Hepatitis: Jiang L

Jiang L, Jiang LS, Cheng NS, Yan LN. · Department of Liver and Vascular Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China. · World J Gastroenterol. · Pubmed #19468999 links to  free full text

Abstract: Prophylactic strategies against hepatitis B virus (HBV) recurrence after liver transplantation (LT) are essential for patients with HBV-related disease. Before LT, lamivudine (LAM) was proposed to be down-graded from first- to second-line therapy. In contrast, adefovir dipivoxil (ADV) has been approved not only as first-line therapy but also as rescue therapy for patients with LAM resistance. Furthermore, combination of ADV and LAM may result in lower risk of ADV resistance than ADV monotherapy. Other new drugs such as entecavir, telbivudine and tenofovir, are probably candidates for the treatment of hepatitis-B-surface-antigen-positive patients awaiting LT. After LT, low-dose intramuscular hepatitis B immunoglobulin (HBIG), in combination with LAM, has been regarded as the most cost-effective regimen for the prevention of post-transplant HBV recurrence in recipients without pretransplant LAM resistance and rapidly accepted in many transplant centers. With the introduction of new antiviral drugs, new hepatitis B vaccine and its new adjuvants, post-transplant HBIG-free therapeutic regimens with new oral antiviral drug combinations or active HBV vaccination combined with adjuvants will be promising, particularly in those patients with low risk of HBV recurrence.

Alkhatib AA, Broaddus RR, Jiang L. · Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX 77030, USA. · Am J Clin Oncol. · Pubmed #18391609 No free full text.

This publication has no abstract.

Zhong R, Pan X, Jiang L, Dai Z, Qin J, Lin B. · Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, PR China. · Electrophoresis. · Pubmed #19319907 No free full text.

Abstract: A novel fabrication process was presented to construct a monolithic integrated PCR-CE microfluidic DNA analysis system as a step toward building a total genetic analysis microsystem. Microfabricated Titanium/Platinum (Ti/Pt) heaters and resistance temperature detectors (RTDs) were integrated on the backside of a bonded glass chip to provide good thermal transfer and precise temperature detection for the drilled PCR-wells. This heater/RTD integration procedure was simple and reliable, and the resulting metal layer can be easily renewed when the Ti/Pt layer was damaged in later use or novel heater/RTD design was desired. A straightforward "RTD-calibration" method was employed to optimize the chip-based thermal cycling conditions. This method was convenient and rapid, comparing with a conventional RTD-calibration/temperature adjustment method. The highest ramping rates of 14 degrees C/s for heating and 5 degrees C/s for cooling in a 3-microL reaction volume allow 30 complete PCR cycles in about 33 min. After effectively passivating the PCR-well surface, successful lambda-phage DNA amplifications were achieved using a two- or three-temperature cycling protocol. The functionality and performance of the integrated microsystem were demonstrated by successful amplification and subsequent on-line separation/sizing of lambda-phage DNA. A rapid assay for Hepatitis B virus, one of the major human pathogens, was performed in less than 45 min, demonstrating that the developed PCR-CE microsystem was capable of performing automatic and high-speed genetic analysis.

Kui X, Sun M, Xie T, Wang W, Jiang L, Yan M, Ma K, Li H. · Institute of Medical Biology, Peking Union Medical College, Kunming, Yunnan, People's Republic of China. · Viral Immunol. · Pubmed #19210228 No free full text.

Abstract: Virus-like particles (VLPs) are highly immunogenic. In this study, gene fragments encoding hepatitis A virus (HAV) vp1 (aa 24-171), a hepatitis E virus (HEV) ORF2 gene fragment encoding aa 431-615, and gene fragments encoding a nine-peptide linker were spliced together. The spliced gene fragments were then inserted into the expression vector pBV220, resulting in the recombinant plasmid pBV-EA342, which expressed a 342-amino acid fusion protein. The fusion protein was expressed in Escherichia coli and specifically reacted to human hepatitis A- and E-positive sera. VLPs were formed during the renaturation of the EA342 fusion protein. The chimeric HAV and HEV VLPs were able to immunize KM mice, and they induced strong anti-HAV and anti-HEV humoral immune responses. These results are promising for future studies.

Cheng X, Wang D, Jiang L, Yang D. · School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong Province 510080, People's Republic of China. · Phytochem Anal. · Pubmed #18446771 No free full text.

Abstract: Corydalis saxicola Bunting (Papaveraceae), a traditional folk medicine, has been used to treat hepatic diseases for a long time. Owing to its signicant clinical effectiveness against hepatitis, cirrhosis and hepatoma, C. saxicola and its preparation are widely applied. In this study, eight alkaloids, namely isocorydine, scoulerine, dehydrocheilanthifoline, dehydrodiscretamine, dehydroisoapocavidine, dehydrocavidine, palmatine and berberine, which have been previously proven to possess potential antitumour activity, were selected as the chemical markers of C. saxicola. To evaluate the quality of C. saxicola, a simple, accurate and reliable HPLC-DAD method was developed for the simultaneous determination of the above eight compounds. Separation was achieved on a Gemini C(18) column (5 microm, 250 x 4.6 mm i.d., Phenomenex Inc., CA, USA) with a gradient solvent system of 20 mM aqueous ammonium acetate-acetonitrile, at a flow-rate of 1.0 mL/min and detected at 270 and 280 nm. All eight calibration curves showed good linearity (R(2) > 0.9992). The method was reproducible with intra- and inter-day variations of less than 5%. The recovery was in the range of 96.09-102.80%. This assay was successfully utilised to quantify the eight alkaloids in C. saxicola from different locations. The results demonstrated that this method is simple, reliable and suitable for the quality control of this medicinal herb.

Jiang L, Qian F, He X, Wang F, Ren D, He Y, Li K, Sun S, Yin C. · Department of Medical Genetics, The Second Military Medical University, 200433 Shanghai, China. · J Gene Med. · Pubmed #17397104 No free full text.

Abstract: BACKGROUND: Chitosan has been shown to possess useful properties such as non-toxicity, high biocompatibility and non-antigenicity that offer advantages for vaccine delivery systems. In this study, we prepared novel chitosan derivative nanoparticles as DNA vaccine carriers and the potential and mechanism of the DNA-nanoparticle complexes in inducing augmented immune responses were explored. METHODS: The pVAX(HBc)DNA-nanoparticle complexes as vaccine delivery systems were studied in several aspects: the protection against DNase I degradation was measured by an in vitro inhibition assay; the sustained expression of the plasmid in vivo was determined by RT-PCR; the elevated uptake efficiency by phagocytes was observed with confocal microscopy; the biocompatibility was evaluated by cytotoxicity and histology assay; the complexes were administrated to C57BL/6 mice and the humoral and cellular immune responses were evaluated by ELISA, IFN-gamma production and cytolytic T lymphocyte (CTL)-specific lysis assay. RESULTS: The remaining relative activity of DNase I after inhibition varied from 32.3% to 77.6%. The complexes were observed with higher uptake efficiency by phagocytes than naked DNA. Three types of nanoparticles did not induce significant cytotoxicity at concentrations<or=400 microg/ml. No specific histological alteration related to the injection of the complexes was observed. The formulations of DNA-nanoparticle complexes significantly enhanced the immunogenicity in several parameters: elevated antibody production, higher level of IFN-gamma secretion, and augmented specific cell lysis. CONCLUSIONS: This study demonstrated the potential of the novel chitosan derivative nanoparticles for safe and effective DNA vaccine delivery.

He X, Jiang L, Wang F, Xiao Z, Li J, Liu LS, Li D, Ren D, Jin X, Li K, He Y, Shi K, Guo Y, Zhang Y, Sun S. · Department of Medical Genetics, The Second Military Medical University, No.800 Xiangyin Road Yangpu district, Shanghai 200433, China. · J Control Release. · Pubmed #16099068 No free full text.

Abstract: Plasmid expressing HBV small envelope antigen was formulated with poly(lactide-co-glycolide-acid) (PLGA) and cetyltrimethylammonium bromide (CTAB) to generate highly uniform microparticles. Controlled release of DNA from these microparticles was demonstrated in vitro and in vivo using flow cytometry and confocal laser scanning microscopy with the focus on localization and quantitatively evaluation of antigen-presenting cells (APCs) involved in the expression of target antigen. Compared to mice vaccinated with naked DNA, mice immunized with PLGA-CTAB-DNA microparticles displayed a much higher percentage of CD11c+, HBsAg-expressing APCs in the draining lymph nodes at 24 h and day 14 postinoculation. In addition, a prolonged transcription of plasmid DNA was detected by RT-PCR in mice immunized with the microparticles. A significantly enhanced immunogenicity of PLGA-CTAB-DNA over naked DNA was observed in immunized mice, including higher levels of antibody production, interferon gamma (IFN-gamma) secretion and cytotoxic T lymphocyte activity. Mice immunized with PLGA-CTAB-DNA microparticles also showed greater efficacy of immunoprotection against challenge of transplanted HBsAg-expressing tumor cells. Our data suggest that controlled release of the PLGA-CTAB-DNA microparticles might involve in the mechanisms of its augmented immunogenicity and enhanced immunoprotection.

He XW, Wang F, Jiang L, Li J, Liu SK, Xiao ZY, Jin XQ, Zhang YN, He Y, Li K, Guo YJ, Sun SH. · Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China. · J Gen Virol. · Pubmed #15722520 links to  free full text

Abstract: The purpose of this work was to assess the ability of plasmid DNA encoding hepatitis B virus (HBV) HBsAg encapsulated in poly(DL-lactide-co-glycolic acid) (PLGA) microparticles to induce local and systemic HBsAg-specific immunity following a single dose of oral immunization. RT-PCR analysis demonstrated prolonged transcription of plasmid DNA, consistent with the sustained expression and presentation of target antigen observed by confocal laser scanning microscopy, in gut-associated lymphocyte tissue (GALT) from mice immunized orally with plasmid DNA encapsulated into PLGA microparticles. Oral administration of PLGA-DNA microparticles induced a long-lasting and stable antigen-specific antibody response, both serum total antibody and intestinal IgA, in BALB/c mice. Mice immunized orally exhibited antigen-specific gamma interferon production and cytotoxic T lymphocyte responses in spleen and GALT after restimulation in vitro with HBsAg or tumour cells stably expressing HBsAg. In contrast, naked DNA vaccines given by intramuscular injection induced only systemic cellular and humoral responses to HBsAg, which were much lower than the responses elicited by oral DNA encapsulated in PLGA microparticles at equivalent doses. The results are encouraging with regard to obtaining good compliance and vaccination coverage with candidate plasmid DNA vaccines, especially in developing countries.

Gu J, Wang L, Che Y, Liu L, Jiang L, Dong S, Li W, Li Q. · Department of Viral Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China. · J Viral Hepat. · Pubmed #15655044 No free full text.

Abstract: The hepatitis C virus (HCV) core protein is supposed to play a critical role in HCV-mediated human liver disease with its capabilities to regulate the growth rate of hepatocytes and to partially contribute to the pathogenesis of hepatocellular carcinoma in association with cellular oncogenes. In this study, to analyse the possible pathological mechanism of the HCV core protein, human primary embryo hepatocytes transfected with HCV core were monitored by immunofluorescence, reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot. The morphological changes and biological properties of the transfected hepatocytes were also studied. The results showed that the HCV core gene integrated in the cellular genome and the protein expressed in the transfected hepatocyte, could be detected following serial passage at both the mRNA and protein level. The proliferation assays indicated that hepatocytes transfected with the HCV core gene alone did not exhibit any tumorigenic tendency. Meanwhile, the morphological alterations of these cells demonstrated obvious changes in size, and large vacuolar degeneration. In conclusion, the hepatocytes transfected with the HCV core gene revealed that the core protein expressed induced pathological changes of degeneration, probably related indirectly to tumorigenicity.

Li Q, Dong C, Wang J, Che Y, Jiang L, Wang J, Sun M, Wang L, Huang J, Ren D. · Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China. · Viral Immunol. · Pubmed #14583147 No free full text.

Abstract: The investigation of antigenic epitopes in hepatitis C virus (HCV) protein suggests that a central sequence combined with multiple antigenic epitopes of HCV might be significant as a potential vaccine candidate. This artificial sequence of combined and modified multiple antigenic epitopic peptides (Hc-B2), containing three B and four T cell epitopes, was constructed and expressed in E. coli. Antigen analysis indicated that this peptide antigen was capable of interacting with anti-sera collected from hepatitis C patients infected by three genotypes of HCV from three different geographic areas of China, respectively. The immunological analysis of this peptide antigen in mice and rhesus suggested that its immunogenicity was effective. However, a complete evaluation of this peptide could not be made as an effective animal model for HCV infection (such as in the chimpanzee) was not available for this study.

Ma D, Wang H, Zhao J, Wang W, Guo N, Jiang L, Zhang D, Sun Y. · The First People's Hospital of Yancheng City, Jiangsu 224001, China. · Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. · Pubmed #12196832 No free full text.

Abstract: BACKGROUND: To evaluate the influence of assays with primer labeled with fluorochrome (Cy5) and dUTP labeled with Cy5 on the signal intensity of the chip for detection of hepatitis B virus (HBV) gene polymorphism. METHODS: The P-region and pre-C/C-region of HBV gene were amplified by polymerase chain reaction (PCR) with Cy5 labeled primer or Cy5 labeled dUTP. The amplicons of the two assays were hybridized with chips, scanned and analyzed by computer software for the detection of HBV gene polymorphism. RESULTS: The signal intensity of assay with Cy5 labeled dUTP was slightly higher than that of assay with Cy5 labeled primer, but non?specific signal intensity of the assay with Cy5 labeled dUTP was higher. The result of 42 samples showed that there was no significant difference between the two assays, and that both had a good repeatability and CV value (15%-20%). CONCLUSIONS: The assay with Cy5 labeled primer may replace the assay with Cy5 labeled dUTP as a routine method to detect HBV gene polymorphism, and it is simpler and cheaper.

Bi S, Lu J, Jiang L, Huang G, Pan H, Jiang Y, Zhang M, Shen X. · Institute of Virology, Chinese Academy of Preventive Medicine, Beijing 100052, China. · Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. · Pubmed #11986741 No free full text.

Abstract: BACKGROUND: To observe the protective effect of hepatitis E virus (HEV) ORF2 recombinant protein expressed in prokaryote cell cynomolgus macaques (cynos) against challenging with wild-type HEV. METHODS: Cynos were immunized with HEV ORF2 recombinant protein and then challenged with wild-type HEV, the unimmunized cynos were used as control. Blood samples were collected and tested to see if there were dynamic changes of ALT and antibody to HEV before and after challenge with wild-type HEV. RESULTS: All the five unimmunized cynos re-presented hepatitis 3 weeks after challenging with wild-type HEV. However, all the five immunized cynos showed no hepatitis and pathological changes. CONCLUSIONS: Cynos can be efficiently protected by immunization with HEV ORF2 recombinant protein against wild-type HEV. This protein can be a promising candidate for HEV vaccine.

Muerhoff AS, Jiang L, Shah DO, Gutierrez RA, Patel J, Garolis C, Kyrk CR, Leckie G, Frank A, Stewart JL, Dawson GJ. · Experimental Biology Research, Abbott Laboratories, North Chicago, Illinois 60064-6269, USA. · Transfusion. · Pubmed #11961241 No free full text.

Abstract: BACKGROUND: Currently, the detection of HCV infection in blood donors relies on the ability of immunoassays to detect circulating HCV antibodies. However, a significant delay exists between the time of infection and the development of antibodies. This delay (window period) can last up to 70 days. The introduction of NAT for the detection of HCV RNA has reduced this window period dramatically. However, NAT is labor intensive, prone to contamination, and expensive as compared with standard serologic tests. STUDY DESIGN AND METHODS: An automated, microparticle-based chemiluminescent assay for the detection of HCV core antigen in human serum and plasma was developed. The specificity and sensitivity of this prototype assay were evaluated by testing a population of normal blood donors and commercially available seroconversion panels. RESULTS: The HCV core antigen assay exhibited a 99.9-percent specificity by detecting a single repeatably reactive sample out of 1004 normal donors tested. Assay sensitivity was determined by comparing the HCV core antigen detection rate with the antibody seroconversion profile and the rate of HCV RNA detection. Among 15 seroconversion panels examined, core antigen was detected in 69 of 70 antibody-negative and/or RNA-positive samples for a sensitivity relative to NAT of 98.6 percent. CONCLUSION: These data indicate that the automated, microparticle-based chemiluminescent HCV core antigen assay can reduce the window period for detection of potentially infected blood donors by 32.7 days, and it represents a viable alternative to HCV RNA testing.

Wang Y, Chen Y, Gu C, Jiang L, Xiang D. · Center for Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. · Zhonghua Gan Zang Bing Za Zhi. · Pubmed #11058944 No free full text.

Abstract: OBJECTIVE: To explore the possibility of establishing more reasonable nomenclatures and diagnostic criteria for patients with severe hepatitis (SH) through analyzing clinical data of 477 cases of SH. METHODS: The clinical characteristics and outcomes of SH were analyzed according to different criteria. RESULTS: Chronic severe hepatitis (CSH) made up 88.5% of total cases of SH. The survival rate in the patients with hepatic encephalopathy was much lower than that without hepatic encephalopathy. About 1/5 of cases of subacute severe hepatitis (SSH) and CSH had neither ascites nor hepatic encephalopathy. When the period of 2 weeks was used in replace of 10 days for the diagnosis for acute severe hepatitis (ASH), the newly added cases were consistent with the characteristics of ASH. CONCLUSION: We suggest dividing SH into 2 types: encephalopathy and non-encephalopathy by using the nomenclature of fulminant hepatitis and severe type hepatitis, respectively. The late-onset form should be added besides of acute form and subacute form. It seems to use the period of 2 weeks as the new definition of onset time for ASH. The criteria of dividing SH into 3 forms, i.e. ascites, encephalopathy and ascites plus encephalopathy, and the nomenclature recommended by the International Association for the Study of the Liver Subcommittee are not satisfactory when used in clinical cases. The typing of CSH remains to be clarified.

Yu Q, Wang J, Jiang L. · Zhongshan Hospital, Shanghai Medical University. Shanghai 200032, China. · Zhonghua Gan Zang Bing Za Zhi. · Pubmed #10712786 No free full text.

Abstract: OBJECTIVE: To determine clinical manifestation and pathological changes in autoimmune hepatitis (AIH) by liver biopsy. METHODS: The clinical manifestation and pathological changes by liver biopsy in 14 AIH patients were investigated retrospectively. RESULTS: Clinically, AIH affects females with a females/male ratio of 13/1, the age range was 28-66 year; there was extended elevation of ALT and AST, hyperglobulinemia, hypergammaglobulinemia with predominant elevation of IgG and different kinds of antibodies. Patients usually had autoimmune diseases with pathological change of typical chronic hepatitis. The levels of globulin (33 approximately 60 g/L), gammaglobulin (23.9% approximately 60.5%), IgG (8.2 approximately 39. 0 g/L), ds-DNA (1.5 approximately 58.0 g/L) in AIH were significantly higher than those of normal (t=9.7, 9.3, 6.2, 3.5, P<0.01). CONCLUSION: AIH has severe liver impairment with many other symptoms due to multi-systemic damage out of liver. AIH is a distinct autoimmune disease.